Association of genetic variation in the transforming growth factor β-1 gene with serum levels and risk of colorectal neoplasia

Cancer Research

Volumn 68, Issue 4, 2008, Pages 1236-1244

  Saltzman, Barbara S ^a,e   Yamamoto, Jennifer F ^a   Decker, Robert ^b   Yokochi, Lance ^c   Theriault, Andre G ^d   Vogt, Thomas M ^b   Le Marchand, Loïc ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b KAISER PERMANENTE   (United States)

^c Pacific Health Research Institute

^d UNIVERSITY OF HAWAII   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADENOCARCINOMA; ADULT; AGED; ALLELE; ARTICLE; ASIAN AMERICAN; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; COLORECTAL TUMOR; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC GROUP; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSFORMING GROWTH FACTOR BETA1; VARIATION (GENETICS);

EID: 39449113621     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2144     Document Type: Article

References (42)

1. Schuster N, Krieglstein K. Mechanisms of TGF-β-mediated apoptosis. Cell Tissue Res 2002;307:1-14.
2. Roman C, Saha D, Beauchamp R. TGF-β and colorectal carcinogenesis. Microsc Res Tech 2001;52:450-7.
3. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
4. Elliott RL, Blobe GC. Role of transforming growth factor β in human cancer. J Clin Oncol 2005;23:2078-93.
5. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type β1. Hum Mol Genet 1999;8:93-7.
6. Yamada Y, Miyauchi A, Takagi Y, Tanaka M, Mizuno M, Harada A. Association of the C-509→T polymorphism, alone of in combination with the T869→C polymorphism, of the transforming growth factor-β1 gene with bone mineral density and genetic susceptibility to osteoporosis in Japanese women. J Mol Med 2001;79:149-56.
7. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. Association of a T29→C polymorphism of the transforming growth factor-β1 gene with genetic suscep tibility to myocardial infarction in Japanese. Circulation 2000;101:2783-7.
8. Hauck EW, Hauptmann A, Schmelz HU, Bein G, Weidner W, Hackstein H. Prospective analysis of single nucleotide polymorphisms of the transforming growth factor β-1 gene in Peyronie's disease. J Urol 2003;169:369-72.
9. Syrris P, Carter ND, Metcalfe JC, et al. Transforming growth factor-β1 gene polymorphisms and coronary artery disease. Clin Sci Lond 1998;95:659-67.
10. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. J Cell Biol 1990;110:1361-7.
11. Cambien F, Ricard S, Troesch A, et al. Polymorphisms of the transforming growth factor-1 gene in relation to myocardial infarction and blood pressure: the Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 1996;28:881-7.
12. Sparks R, Bigler J, Sibert JG, Potter JD, Yasui Y, Ulrich CM. TGFβ1 polymorphism (L10P) and risk of colorectal adenomatous and hyperplastic polyps. Int J Epidemiol 2004;33:955-61.
13. Macarthur M, Sharp L, Hold GL, Little J, El Omar EM. The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev 2005;14:1613-8.
14. Berndt SI, Huang W, Chatterjee N, et al. Transforming growth factor β1 (TGFB1) gene polymorphisms and risk of advanced colorectal adenoma. Carcinogenesis 2007;28:1965-70.
15. Le Marchand L, Donlon T, Seifried A, Kaaks R, Rinaldi S, Wilkens LR. Association of a common polymorphism in the human GH1 gene with colorectal neoplasia. J Natl Cancer Inst 2002;94:454-60.
16. Le Marchand L, Hankin JH, Wilkens LR, et al. Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:1259-66.
17. Hankin JH, Yoshizawa CN, Kolonel LN. Reproducibility of a diet history in older men in Hawaii. Nutr Cancer 1990;13:129-40.
18. Hankin JH, Wilkens LR, Kolonel LN, Yoshizawa CN. Validation of a quantitative diet history method in Hawaii. Am J Epidemiol 1991;133:616-28.
19. The International HapMap Project. Nature 2003;426:789-96.
20. Haiman CA, Stram DO, Pike MC, et al. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 2003;12:2679-92.
21. Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer 2004;4:519-27.
22. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005;76:887-93.
23. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
24. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
25. Stram DO, Haiman CA, Hirschhorn JN, et al. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003;55:27-36.
26. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005;37:1217-23.
27. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
28. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005;76:449-62.
29. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-9.
30. Shim KS, Kim KH, Han WS, Park EB. Elevated serum levels of transforming growth factor-β1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer 1999;85:554-61.
31. Dunning AM, Ellis PD, McBride S, et al. A transforming growth factor β1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003;63:2610-5.
32. Ziv E, Cauley J, Morin PA, Saiz R, Browner WS. Association between the T29→C polymorphism in the transforming growth factor β1 gene and breast cancer among elderly white women: The Study of Osteoporotic Fractures. JAMA 2001;285:2859-63.
33. Kaklamani VG, Baddi L, Liu J, et al. Combined genetic assessment of transforming growth factor-β signaling pathway variants may predict breast cancer risk. Cancer Res 2005;65:3454-61.
34. Krippl P, Langsenlehner U, Renner W, et al. The L10P polymorphism of the transforming growth factor-β1 gene is not associated with breast cancer risk. Cancer Lett 2003;201:181-4.
35. Le Marchand L, Haiman CA, van den BD, Wilkens LR, Kolonel LN, Henderson BE. T29C polymorphism in the transforming growth factor β1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 2004;13:412-5.
36. Jin Q, Hemminki K, Grzybowska E, et al. Polymorphisms and haplotype structures in genes for transforming growth factor β1 and its receptors in familial and unselected breast cancers. Int J Cancer 2004;112:94-9.
37. Ewart-Toland A, Chan JM, Yuan J, Balmain A, Ma J. A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:759-64.
38. Kang D, Lee KM, Park SK, et al. Lack of association of transforming growth factor-β1 polymorphisms and haplotypes with prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Trial. Cancer Epidemiol Biomarkers Prev 2007;16:1303-5.
39. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 2003;100:8430-5.
40. Reiss M, Barcellos-Hoff MH. Transforming growth factor-β in breast cancer: a working hypothesis. Breast Cancer Res Treat 1997;45:81-95.
41. Roberts AB, Wakefield LM. The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci U S A 2003;100:8621-3.
42. Kretzschmar M. Transforming growth factor-β and breast cancer: transforming growth factor-β/SMAD signaling defects and cancer. Breast Cancer Res 2000;2:107-15.